The Emerging Role of Brazil in Clinical Trial Conduct for Transplantation

The Emerging Role of Brazil in Clinical Trial Conduct for Transplantation

Author Tedesco-Silva Junior, Hélio Autor UNIFESP Google Scholar
Felipe, Claudia Rosso Autor UNIFESP Google Scholar
Abbud-Filho, M. Google Scholar
Garcia, V. Google Scholar
Medina-Pestana, J. O. Autor UNIFESP Google Scholar
Institution Universidade Federal de São Paulo (UNIFESP)
FAMERP HB FUNFARME
Santa Casa Misericordia
Abstract Brazil is a country with over 190 000 000 inhabitants and a health system composed of a large public, government managed system. Between 1999 and 2010 the number of deceased donors increased by 161%, from 3.8 to 9.9 pmp, and the number of solid organ transplants increased by 121%, from 2891 to 6402. This growth was a consequence of the creation of a well-organized national transplant program. Government funding, decentralization and educational investment in transplant coordinators and related professional were decisive. in 2009 Brazil was the second largest country in the absolute number of kidney transplants (n = 4259). There are significant region disparities in performance which are mainly due to the development status. Improvements in transplant and research regulations resulted in an increasing participation of Brazilian transplant centers in multicenter trials, reaching over 44 studies during the last 11 years. Brazilian centers have been involved in clinical trials using everolimus, sirolimus, fingolimod, mycophenolate mofetyl, mycophenolate sodium, tacrolimus modified-release, sotrastaurin, belatacept, JAK3 inhibitor CP690,550 and valganciclovir. the still increasing number of transplants performed every year along with more efficient regulatory and sanitary analysis, organized clinical research programs and reduction in region performance disparities will eventually increase even more the participation of Brazil in trials worldwide.
Keywords Clinical trial
immunosuppression
kidney transplantation
organ donation
Language English
Sponsor Novartis
Roche
Pfizer
Wyeth
Bristol Meyer Squibb
Jansen-Cilag
Astelas
Date 2011-07-01
Published in American Journal of Transplantation. Hoboken: Wiley-Blackwell, v. 11, n. 7, p. 1368-1375, 2011.
ISSN 1600-6135 (Sherpa/Romeo, impact factor)
Publisher Wiley-Blackwell
Extent 1368-1375
Origin http://dx.doi.org/10.1111/j.1600-6143.2011.03564.x
Access rights Open access Open Access
Type Review
Web of Science ID WOS:000292264000007
URI http://repositorio.unifesp.br/handle/11600/33827

Show full item record




File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account